Video

Q&A with Seth Karol, MD: Risk Factors for Bone Toxicity for Patients with ALL

Author(s):

Seth Karol, MD, St. Jude's Children's Research Center discussed several ways in which he and his colleagues intensified therapy over the years and referred to a key toxicity that had emerged from the two drugs they used.

Seth Karol, MD, St. Jude's Children's Research Center discussed several ways in which he and his colleagues intensified therapy over the years and referred to a key toxicity that had emerged from the two drugs they used.

Karol understands further studies are necessary to ensure their methods of reducing risks don't affect the success of curing diseases.

Related Videos
Davide Matino, MD, MSc: Bringing Marstacimab Treatment to Hemophilia A and B
Ben Samelson-Jones,Ben Samelson-Jones, MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy
Françoise Bernaudin, MD: A Decade of Follow-up Reveals allo-SCT Superiority Over SOC for Sickle Cell Anemia
Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH
Steven W. Pipe, MD: Fitusiran With Anti-Thrombin Modulation Yields Effective Bleed Control, Reduces Infusions
Highlighting the Danger of SCI Progression during iTTP Remission, with Shruti Chaturvedi, MBSS, MS
Caroline Piatek, MD: Improving Patient-Reported Outcomes in PNH With Danicopan Add-on Therapy
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
Jörn Schattenberg, MD | Credit: Novo Nordisk
Jörn Schattenberg, MD | Credit: Novo Nordisk
© 2024 MJH Life Sciences

All rights reserved.